Equities analysts expect that Insulet Co. (NASDAQ:PODD) will post $178.94 million in sales for the current quarter, according to Zacks. Nine analysts have provided estimates for Insulet’s earnings. The highest sales estimate is $180.40 million and the lowest is $177.80 million. Insulet reported sales of $151.08 million during the same quarter last year, which indicates a positive year-over-year growth rate of 18.4%. The firm is scheduled to issue its next earnings report after the market closes on Tuesday, November 5th.
On average, analysts expect that Insulet will report full-year sales of $710.40 million for the current financial year, with estimates ranging from $707.55 million to $715.13 million. For the next fiscal year, analysts expect that the firm will report sales of $841.71 million, with estimates ranging from $792.42 million to $872.70 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Insulet.
Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Insulet had a net margin of 2.66% and a return on equity of 7.85%. The company had revenue of $177.10 million during the quarter, compared to the consensus estimate of $163.63 million. During the same period last year, the company earned ($0.03) earnings per share. Insulet’s revenue for the quarter was up 42.5% on a year-over-year basis.
PODD has been the subject of a number of analyst reports. Raymond James raised their price objective on shares of Insulet from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Svb Leerink raised their price objective on shares of Insulet from $160.00 to $185.00 and gave the stock an “outperform” rating in a report on Tuesday, September 24th. Guggenheim downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, October 3rd. They noted that the move was a valuation call. Leerink Swann reaffirmed an “outperform” rating and set a $185.00 price objective (up from $160.00) on shares of Insulet in a report on Tuesday, September 24th. Finally, Canaccord Genuity downgraded shares of Insulet from a “buy” rating to a “hold” rating and raised their price objective for the stock from $135.00 to $145.00 in a report on Friday. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Insulet presently has an average rating of “Buy” and an average price target of $145.36.
Shares of NASDAQ:PODD traded down $2.74 during midday trading on Tuesday, reaching $153.74. 610,330 shares of the company’s stock were exchanged, compared to its average volume of 1,072,952. The company’s 50 day simple moving average is $154.99 and its two-hundred day simple moving average is $124.63. The firm has a market capitalization of $9.43 billion, a PE ratio of 3,074.80 and a beta of 1.02. Insulet has a 12 month low of $70.80 and a 12 month high of $168.98. The company has a debt-to-equity ratio of 2.43, a quick ratio of 3.91 and a current ratio of 4.72.
In related news, SVP Michael P. Spears sold 4,153 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.12, for a total transaction of $606,836.36. Following the completion of the sale, the senior vice president now owns 22,626 shares in the company, valued at approximately $3,306,111.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Shacey Petrovic sold 649 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Advisors Preferred LLC acquired a new stake in Insulet in the 2nd quarter valued at about $38,000. Harvest Fund Management Co. Ltd acquired a new stake in Insulet in the 2nd quarter valued at about $43,000. Meridian Wealth Management LLC acquired a new stake in Insulet in the 1st quarter valued at about $48,000. Mitsubishi UFJ Securities Holdings Co. Ltd. acquired a new stake in Insulet in the 2nd quarter valued at about $97,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Insulet in the 2nd quarter valued at about $119,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Recommended Story: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.